Phase 1 study of ombrabulin in combination with cisplatin (CDDP) in Japanese patients with advanced solid tumors

摘要

Combination therapy of ombrabulin 25 mg/m(2) with cisplatin 75 mg/m(2) once every 3 weeks was well tolerated and established as the recommend dose in Japanese patients with advanced solid tumors.In clinical studies in Western countries, the recommended dose of combination ombrabulin a vascular disrupting agent, with cisplatin is 25 mg/m(2) ombrabulin with 75 mg/m(2) cisplatin every 3 weeks. Here, we report the first Phase 1 study of this treatment regimen in Japanese patients with advanced solid tumors.